背景:作为一种传统的中草药,五味子表现出各种效果,如肝脏保护,血糖调节,血脂调节,免疫功能调节,抗抑郁活性,等。然而,由于其复杂的组成,不同的起源,和药物作用取决于复杂的化合物组,不同产地的五味子木脂素成分存在差异。因此,目前很难使用单一的定性质量控制指标来评估不同来源植物的药材质量。
目的:本文旨在研究不同产地五味子木脂素成分之间的潜在关系,建立稳定的评价指标,从多个角度确定五味子木脂素含量。
方法:在本研究中,我们收集了中国七个主要产地的中国海参样本,并随机抽样各产地6-9批,共60批。通过HPLC测定木酚素含量,分析了五味子木脂素各组分与五味子A含量的比例分布规律。结合网络药理学和样本间的差异分析,确定了用作质量标记的稳定有效物质。
结果:五味子木脂素含量之间存在一定的相关性,可以确定五味子A与中国其他木脂素之间的相关性。各组分与指示组分五味子A的比例分布均匀,在一定程度上反映了五味子的木酚素含量。四种物质(五味子醇A,五味子B,schisantherinA,和五味子乙素C)通过网络药理学结合HCA的分析结果进行测定,PCA和PLS-DA进一步优化模型。他们与核心目标表现出了很强的联系,对主成分的贡献率很大,每批样品含量稳定,提示这些成分可能是五味子木脂素的主要活性物质。因此,通过考察各组分比例的一致性,可以作为评价中国山竹优劣的主要指标。
结论:该方法可以直观地评价五味子中主要木脂素的含量。该质量评价模型是对中国山葵多组分综合评价体系的探索,为中药材质量评价体系提供了新的思路。
BACKGROUND: As a traditional Chinese herbal medicine, Schisandra chinensis exhibits various effects such as liver protection, blood sugar regulation, blood lipid regulation, immune function regulation, antidepressant activity, etc. However, because of its intricate composition, diverse origins, and medicinal effects depending on complex compound groups, there are differences in the lignan composition of S. chinensis from different origins. Therefore, it is currently difficult to evaluate the quality of medicinal materials from plants of different origins using a single qualitative quality control index.
OBJECTIVE: This paper aims to investigate the potential relationship between the lignan components of S. chinensis from different origins and to establish stable assessment indices for determining the lignan content of S. chinensis from multiple perspectives.
METHODS: In this study, we collected S. chinensis samples of seven major origins in China, and randomly sampled 6-9 batches of each origin for a total of 60 batches. The lignan content was determined by HPLC, and its distribution law of the ratio of each lignan component of S. chinensis to Schisandrol A content was analyzed. Combining network pharmacology and differential analysis between samples, the stable and effective substances used as quality markers were determined.
RESULTS: There were some correlations among the lignan contents of S. chinensis, some correlations between schisandrin A and other lignans of S. chinensis could be determined. The ratio of each component to the indicator component schisandrol A was evenly distributed and reflected the lignan content of S. chinensis to some extent. Four substances (schisandrol A, schisandrol B, schisantherin A, and schisandrin C) were determined by network pharmacology combined with the analysis results of HCA, PCA and PLS-DA to further optimize the model. They displayed a strong connection with the core target, a large contribution rate to the principal components, and a stable content in each batch of samples, suggesting that these components may be the main active substances of S. chinensis lignans. Therefore, they could be used as main indicators evaluating the advantages and disadvantages of S. chinensis by examining the consistency of component proportions.
CONCLUSIONS: This method can intuitively evaluate the content of main lignans in S. chinensis. This quality assessment model is an exploration of the multi-component comprehensive evaluation system of S. chinensis, providing a new concept for the quality evaluation system of Chinese herbal medicines.